Other analysts have also issued research reports about the stock. ValuEngine lowered shares of Sarepta Therapeutics from a buy rating to a hold rating in a report on Thursday, August 8th. Zacks Investment Research raised shares of Sarepta Therapeutics from a hold rating to a buy rating and set a $130.00 price objective for the company in a report on Wednesday, May 8th. William Blair reaffirmed a buy rating on shares of Sarepta Therapeutics in a report on Friday, August 9th. HC Wainwright set a $267.00 price objective on shares of Sarepta Therapeutics and gave the stock a buy rating in a report on Monday, June 17th. Finally, Evercore ISI reaffirmed a buy rating and set a $200.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, August 8th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and twenty have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average price target of $208.29.
NASDAQ:SRPT traded down $0.82 during mid-day trading on Wednesday, hitting $122.77. The company’s stock had a trading volume of 15,723 shares, compared to its average volume of 1,257,933. Sarepta Therapeutics has a fifty-two week low of $95.21 and a fifty-two week high of $165.87. The company has a debt-to-equity ratio of 0.35, a current ratio of 12.17 and a quick ratio of 11.15. The firm has a market cap of $9.23 billion, a P/E ratio of -22.57 and a beta of 2.01. The company has a fifty day simple moving average of $145.75.
Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($3.74) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.08) by ($2.66). The firm had revenue of $94.67 million for the quarter, compared to analyst estimates of $91.05 million. Sarepta Therapeutics had a negative return on equity of 56.64% and a negative net margin of 165.52%. The business’s quarterly revenue was up 28.8% on a year-over-year basis. During the same period in the previous year, the business posted ($1.67) EPS. Sell-side analysts expect that Sarepta Therapeutics will post -4.89 EPS for the current year.
In other Sarepta Therapeutics news, Director Richard Barry acquired 1,300 shares of Sarepta Therapeutics stock in a transaction on Monday, August 12th. The shares were purchased at an average cost of $122.50 per share, with a total value of $159,250.00. Following the completion of the purchase, the director now owns 3,173,365 shares in the company, valued at $388,737,212.50. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 23rd. The shares were sold at an average price of $120.00, for a total transaction of $1,200,000.00. Following the completion of the transaction, the director now directly owns 21,717 shares in the company, valued at $2,606,040. The disclosure for this sale can be found here. Insiders have bought 21,252 shares of company stock worth $2,612,634 over the last three months. 6.60% of the stock is owned by insiders.
A number of hedge funds have recently made changes to their positions in SRPT. Evolution Wealth Advisors LLC bought a new position in Sarepta Therapeutics in the second quarter valued at approximately $25,000. Trust Co. of Vermont boosted its stake in Sarepta Therapeutics by 2,125.0% in the second quarter. Trust Co. of Vermont now owns 178 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 170 shares during the last quarter. Steward Partners Investment Advisory LLC bought a new position in shares of Sarepta Therapeutics during the second quarter worth $32,000. Lindbrook Capital LLC bought a new position in shares of Sarepta Therapeutics during the first quarter worth $35,000. Finally, Quadrant Capital Group LLC bought a new position in shares of Sarepta Therapeutics during the first quarter worth $51,000. 95.57% of the stock is currently owned by hedge funds and other institutional investors.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.
Featured Story: Cost of Goods Sold (COGS)
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.